{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T22:57:05Z","timestamp":1771973825513,"version":"3.50.1"},"reference-count":50,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"46","license":[{"start":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T00:00:00Z","timestamp":1763078400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"the Scientific Research Fund of Education Department of Yunnan Province","award":["2025J0784"],"award-info":[{"award-number":["2025J0784"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,11,14]]},"abstract":"<jats:p>\n                    Cisplatin resistance is a major contributor to treatment failure in ovarian cancer (OC). This study investigates the mechanisms of action and therapeutic targets of\n                    <jats:italic toggle=\"yes\">Stephania tetrandra<\/jats:italic>\n                    S. Moorefor cisplatin-resistant OC. OC datasets were obtained from the gene expression omnibus database, and differentially expressed genes were identified through weighted gene co-expression network analysis. Cisplatin resistance-related targets were screened using the GeneCards, OMIM, and MsigDB databases, while active components of\n                    <jats:italic toggle=\"yes\">S tetrandra<\/jats:italic>\n                    were retrieved from the TCMSP, ETCM, and BATMAN databases. Commonly shared genes between these 2 sets were selected for further analysis. A protein\u2013protein interaction network was constructed using the STRING database, and 4 machine learning algorithms were integrated to identify core targets. Binding affinities were evaluated by molecular docking with AutoDock Vina. Molecular dynamics simulations were then conducted to assess the stability of the ligand-target complexes. We performed ADMET analysis to assess the pharmacokinetic properties and drug-likeness of\n                    <jats:italic toggle=\"yes\">S tetrandra<\/jats:italic>\n                    . Machine learning algorithms further identified 8 core targets including threonine tyrosine kinase (TTK), AURKA, B-cell lymphoma 2, vitamin D receptor, NFKB1, cyclin dependent kinase 1, DNMT1, and SMAD7. Gene ontology and Kyoto Encyclopedia of Genes and Genomes pathway enrichment analyses revealed that these targets were significantly enriched in pathways such as the PI3K-AKT, cell cycle regulation, p53 signaling pathway, and platinum resistance pathway. Receiver operating characteristic curve analysis demonstrated diagnostic potential for all genes except SMAD7 (AUC\u2005=\u20050.603\u2005&lt;\u20050.7). Immune infiltration analysis indicated a positive correlation between AURKA\/TTK expression and M0\/M1 macrophage infiltration (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005&lt;.05). Molecular dynamics simulations demonstrated that hesperidin, cissamine and tetrandrine exhibited strong binding affinities toward AURKA, vitamin D receptor, and TTK. Future studies are encouraged to focus on the experimental validation of these compounds and delve deeper into the possible mechanisms of drug resistance, aiming to improve their therapeutic effectiveness and real-world applicability.\n                  <\/jats:p>","DOI":"10.1097\/md.0000000000045860","type":"journal-article","created":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T21:01:55Z","timestamp":1763154115000},"page":"e45860","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Exploring the mechanism of Stephania tetrandra S. Moore in the treatment of cisplatin resistance against ovarian cancer through integration of network pharmacology and molecular docking"],"prefix":"10.1097","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2601-7030","authenticated-orcid":false,"given":"Yuanyuan","family":"Zhong","sequence":"first","affiliation":[{"name":"Department of Pharmacy, The Third People\u2019s Hospital of Yunnan Province, Kunming, Yunnan, China"},{"name":"Yunnan Cancer Hospital, The Third Affiliated Hospital of Kunming Medical University, Peking University Cancer Hospital Yunnan, Kunming, Yunnan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shanshan","family":"Cai","sequence":"additional","affiliation":[{"name":"Division of Biomedical and Life Sciences, Faculty of Health and Medicine, Lancaster University, Lancaster, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunyue","family":"Fang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Third People\u2019s Hospital of Yunnan Province, Kunming, Yunnan, China"},{"name":"College of Pharmacy, Dali University, Dali, Yunnan, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-4999-9123","authenticated-orcid":false,"given":"Wei","family":"Dai","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Third People\u2019s Hospital of Yunnan Province, Kunming, Yunnan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20251121","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.3390\/cancers14092230","article-title":"Worldwide burden, risk factors, and temporal trends of ovarian cancer: a global study.","volume":"14","author":"Huang","year":"2022","journal-title":"Cancers (Basel)"},{"key":"R2-20251121","doi-asserted-by":"crossref","first-page":"102983","DOI":"10.1016\/j.eclinm.2024.102983","article-title":"Worldwide patterns and trends in ovarian cancer incidence by histological subtype: a population-based analysis from 1988 to 2017.","volume":"79","author":"Wei","year":"2025","journal-title":"EClinicalMedicine"},{"key":"R3-20251121","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3892\/ijo.2024.5619","article-title":"Advances in the role of GPX3 in ovarian cancer (Review).","volume":"64","author":"Geng","year":"2024","journal-title":"Int J Oncol"},{"key":"R4-20251121","doi-asserted-by":"crossref","first-page":"1581157","DOI":"10.3389\/fonc.2025.1581157","article-title":"Advancements in artificial intelligence for ultrasound diagnosis of ovarian cancer: a comprehensive review.","volume":"15","author":"Tang","year":"2025","journal-title":"Front Oncol"},{"key":"R5-20251121","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.3390\/ijms26062545","article-title":"Precision medicine in high-grade serous ovarian cancer: targeted therapies and the challenge of chemoresistance.","volume":"26","author":"Polaj\u017eer","year":"2025","journal-title":"Int J Mol Sci"},{"key":"R6-20251121","doi-asserted-by":"crossref","first-page":"115587","DOI":"10.1016\/j.ejca.2025.115587","article-title":"Veliparib concomitant with first-line chemotherapy and as maintenance therapy in ovarian cancer: final overall survival and disease-related symptoms results.","volume":"225","author":"Coleman","year":"2025","journal-title":"Eur J Cancer"},{"key":"R7-20251121","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1093\/carcin\/bgae029","article-title":"Transposable elements alter gene expression and may impact response to cisplatin therapy in ovarian cancer.","volume":"45","author":"Mombach","year":"2024","journal-title":"Carcinogenesis"},{"key":"R8-20251121","doi-asserted-by":"crossref","first-page":"103855","DOI":"10.1016\/j.dnarep.2025.103855","article-title":"Treatment of human cells with the anti-cancer drug cisplatin results in the caspase-dependent release of adduct-containing cell-free DNA.","volume":"151","author":"Yerrapragada","year":"2025","journal-title":"DNA Repair (Amst)"},{"key":"R9-20251121","doi-asserted-by":"crossref","first-page":"114656","DOI":"10.1016\/j.yexcr.2025.114656","article-title":"Constructing a co-culture model of cancer-associated fibroblasts and ovarian cancer organoids and studying mechanisms of drug resistance.","volume":"450","author":"Ma","year":"2025","journal-title":"Exp Cell Res"},{"key":"R10-20251121","doi-asserted-by":"crossref","first-page":"e473114","DOI":"10.1200\/EDBK-25-473114","article-title":"State of the art: therapies now and around the corner for gynecologic cancers.","volume":"45","author":"Moore","year":"2025","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"R11-20251121","doi-asserted-by":"crossref","first-page":"82","DOI":"10.3892\/or.2022.8293","article-title":"Molecular mechanisms of platinum\u2011based chemotherapy resistance in ovarian cancer (Review).","volume":"47","author":"Yang","year":"2022","journal-title":"Oncol Rep"},{"key":"R12-20251121","doi-asserted-by":"crossref","first-page":"3045","DOI":"10.21873\/anticanres.17669","article-title":"Amentoflavone enhances the anti-tumor activity of regorafenib by promoting apoptosis and inhibiting NF-\u03baB-mediated metastasis in hepatocellular carcinoma.","volume":"45","author":"Lin","year":"2025","journal-title":"Anticancer Res"},{"key":"R13-20251121","doi-asserted-by":"crossref","first-page":"e20240027","DOI":"10.1590\/1984-3143-ar2024-0027","article-title":"Withanolide derivatives: natural compounds with anticancer potential offer low toxicity to fertility and ovarian follicles in mice.","volume":"21","author":"Palomino","year":"2024","journal-title":"Anim Reprod"},{"key":"R14-20251121","doi-asserted-by":"crossref","first-page":"106222","DOI":"10.1016\/j.fitote.2024.106222","article-title":"Alkaloids in cancer therapy: targeting the tumor microenvironment and metastasis signaling pathways.","volume":"179","author":"Koochaki","year":"2024","journal-title":"Fitoterapia"},{"key":"R15-20251121","doi-asserted-by":"crossref","first-page":"e70052","DOI":"10.1002\/ddr.70052","article-title":"Andrographolide mitigates cisplatin resistance by inhibiting SPP1 regulated NF-kB\/iNOS\/COX-2 and PI3K\/AKT pathway in cisplatin resistant cervical carcinoma cells.","volume":"86","author":"Pasha","year":"2025","journal-title":"Drug Dev Res"},{"key":"R16-20251121","doi-asserted-by":"crossref","first-page":"189349","DOI":"10.1016\/j.bbcan.2025.189349","article-title":"Phytochemical intervention in BCRP-driven cancer drug resistance: a comprehensive review.","volume":"1880","author":"Anish Ruban","year":"2025","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"R17-20251121","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s11101-020-09673-w","article-title":"A critical review: traditional uses, phytochemistry, pharmacology and toxicology of Stephania tetrandra S. Moore (Fen Fang Ji).","volume":"19","author":"Jiang","year":"2020","journal-title":"Phytochem Rev"},{"key":"R18-20251121","doi-asserted-by":"crossref","first-page":"3047","DOI":"10.1039\/D0OB00078G","article-title":"A modular approach to the bisbenzylisoquinoline alkaloids tetrandrine and isotetrandrine.","volume":"18","author":"Sch\u00fctz","year":"2020","journal-title":"Org Biomol Chem"},{"key":"R19-20251121","doi-asserted-by":"crossref","first-page":"1387756","DOI":"10.3389\/fphar.2024.1387756","article-title":"Tetrandrine inhibits aldosterone synthesis by covalently targeting CYP11A1 to attenuate hypertension.","volume":"15","author":"Chu","year":"2024","journal-title":"Front Pharmacol"},{"key":"R20-20251121","doi-asserted-by":"crossref","first-page":"102038","DOI":"10.1016\/j.mcp.2025.102038","article-title":"Assessment of cancer-associated fibroblast signature genes in ovarian cancer patients: impact on immunity, drug resistance, and prognosis.","volume":"83","author":"Zhang","year":"2025","journal-title":"Mol Cell Probes"},{"key":"R21-20251121","doi-asserted-by":"crossref","first-page":"1.30.1","DOI":"10.1002\/cpbi.5","article-title":"The GeneCards Suite: from gene data mining to disease genome sequence analyses.","volume":"54","author":"Stelzer","year":"2016","journal-title":"Curr Protoc Bioinformatics"},{"key":"R22-20251121","doi-asserted-by":"crossref","first-page":"D1110","DOI":"10.1093\/nar\/gkad926","article-title":"BATMAN-TCM 2.0: an enhanced integrative database for known and predicted interactions between traditional Chinese medicine ingredients and target proteins.","volume":"52","author":"Kong","year":"2024","journal-title":"Nucleic Acids Res"},{"key":"R23-20251121","doi-asserted-by":"crossref","first-page":"D976","DOI":"10.1093\/nar\/gky987","article-title":"ETCM: an encyclopaedia of traditional Chinese medicine.","volume":"47","author":"Xu","year":"2019","journal-title":"Nucleic Acids Res"},{"key":"R24-20251121","doi-asserted-by":"crossref","first-page":"D730","DOI":"10.1093\/nar\/gkae1113","article-title":"The STRING database in 2025: protein networks with directionality of regulation.","volume":"53","author":"Szklarczyk","year":"2025","journal-title":"Nucleic Acids Res"},{"key":"R25-20251121","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1002\/jcc.20945","article-title":"CHARMM-GUI: a web-based graphical user interface for CHARMM.","volume":"29","author":"Jo","year":"2008","journal-title":"J Comput Chem"},{"key":"R26-20251121","doi-asserted-by":"crossref","first-page":"e70186","DOI":"10.1002\/jbt.70186","article-title":"Polyphyllin VII enhances the antitumor activity of cisplatin in non-small cell lung cancer cells by inducing ferroptosis and enhancing apoptosis.","volume":"39","author":"Wu","year":"2025","journal-title":"J Biochem Mol Toxicol"},{"key":"R27-20251121","doi-asserted-by":"crossref","first-page":"e70501","DOI":"10.1111\/jcmm.70501","article-title":"Cinobufagin enhances the sensitivity of cisplatin-resistant lung cancer cells to chemotherapy by inhibiting the PI3K\/AKT and MAPK\/ERK pathways.","volume":"29","author":"Zhang","year":"2025","journal-title":"J Cell Mol Med"},{"key":"R28-20251121","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.3390\/cancers16162805","article-title":"Aurora kinase A inhibition potentiates platinum and radiation cytotoxicity in non-small-cell lung cancer cells and induces expression of alternative immune checkpoints.","volume":"16","author":"Liu","year":"2024","journal-title":"Cancers (Basel)"},{"key":"R29-20251121","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1158\/0008-5472.CAN-03-2907","article-title":"Aurora-A kinase regulates telomerase activity through c-Myc in human ovarian and breast epithelial cells.","volume":"64","author":"Yang","year":"2004","journal-title":"Cancer Res"},{"key":"R30-20251121","doi-asserted-by":"crossref","first-page":"9603271231185774","DOI":"10.1177\/09603271231185774","article-title":"Anlotinib induces apoptosis and second growth\/mitosis phase block in cisplatin-resistant ovarian cancer cells via the Aurora kinase A\/p53 pathway.","volume":"42","author":"Wang","year":"2023","journal-title":"Hum Exp Toxicol"},{"key":"R31-20251121","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1177\/00220345241309624","article-title":"Targeting Aurora A to overcome cisplatin resistance in head and neck cancer.","volume":"104","author":"Li","year":"2025","journal-title":"J Dent Res"},{"key":"R32-20251121","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13008-018-0040-6","article-title":"The functional diversity of Aurora kinases: a comprehensive review.","volume":"13","author":"Willems","year":"2018","journal-title":"Cell Div"},{"key":"R33-20251121","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1146\/annurev-biochem-061611-090435","article-title":"The MPS1 family of protein kinases.","volume":"81","author":"Liu","year":"2012","journal-title":"Annu Rev Biochem"},{"key":"R34-20251121","doi-asserted-by":"crossref","first-page":"104355","DOI":"10.1016\/j.drudis.2025.104355","article-title":"The spindle assembly checkpoint: molecular mechanisms and kinase-targeted drug discovery.","volume":"30","author":"Lima","year":"2025","journal-title":"Drug Discov Today"},{"key":"R35-20251121","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1038\/s41419-021-04429-6","article-title":"TTK inhibition increases cisplatin sensitivity in high-grade serous ovarian carcinoma through the mTOR\/autophagy pathway.","volume":"12","author":"Qi","year":"2021","journal-title":"Cell Death Dis"},{"key":"R36-20251121","doi-asserted-by":"crossref","first-page":"191","DOI":"10.4196\/kjpp.24.132","article-title":"Tasquinimod promotes the sensitivity of ovarian cancer cells to cisplatin by down-regulating the HDAC4\/p21 pathway.","volume":"29","author":"Li","year":"2025","journal-title":"Korean J Physiol Pharmacol"},{"key":"R37-20251121","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1038\/s41416-018-0043-8","article-title":"The mechanism study of lentiviral vector carrying methioninase enhances the sensitivity of drug-resistant gastric cancer cells to Cisplatin.","volume":"118","author":"Xin","year":"2018","journal-title":"Br J Cancer"},{"key":"R38-20251121","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s00280-024-04748-3","article-title":"Targeting on the PI3K\/mTOR: a potential treatment strategy for clear cell ovarian carcinoma.","volume":"95","author":"Zheng","year":"2025","journal-title":"Cancer Chemother Pharmacol"},{"key":"R39-20251121","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.3390\/molecules30112377","article-title":"Fenbendazole exhibits antitumor activity against cervical cancer through dual targeting of cancer cells and cancer stem cells: evidence from in vitro and in vivo models.","volume":"30","author":"Lei","year":"2025","journal-title":"Molecules"},{"key":"R40-20251121","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1080\/15548627.2015.1072670","article-title":"VDR\/vitamin D receptor regulates autophagic activity through ATG16L1.","volume":"12","author":"Sun","year":"2016","journal-title":"Autophagy"},{"key":"R41-20251121","doi-asserted-by":"crossref","first-page":"4675","DOI":"10.3390\/ijms24054675","article-title":"Exploiting vitamin D receptor and its ligands to target squamous cell carcinomas of the head and neck.","volume":"24","author":"Koll","year":"2023","journal-title":"Int J Mol Sci"},{"key":"R42-20251121","doi-asserted-by":"crossref","first-page":"117111","DOI":"10.1016\/j.taap.2024.117111","article-title":"Hesperidin attenuates radiation-induced ovarian failure in rats: emphasis on TLR-4\/NF-\u0138B signaling pathway.","volume":"492","author":"Mohamed","year":"2024","journal-title":"Toxicol Appl Pharmacol"},{"key":"R43-20251121","first-page":"5569","article-title":"Hesperidin inhibits ovarian cancer cell viability through endoplasmic reticulum stress signaling pathways.","volume":"14","author":"Zhao","year":"2017","journal-title":"Oncol Lett"},{"key":"R44-20251121","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.2174\/0118715206304668240729093158","article-title":"Cyclanoline reverses cisplatin resistance in bladder cancer cells by inhibiting the JAK2\/STAT3 pathway.","volume":"24","author":"Li","year":"2024","journal-title":"Anticancer Agents Med Chem"},{"key":"R45-20251121","doi-asserted-by":"crossref","first-page":"177635","DOI":"10.1016\/j.ejphar.2025.177635","article-title":"Tetrandrine and adriamycin reverse multidrug resistance by regulating NLRP3\/Caspase-1\/GSDMD signaling in human breast cancer cells.","volume":"998","author":"Xin","year":"2025","journal-title":"Eur J Pharmacol"},{"key":"R46-20251121","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s12935-017-0410-1","article-title":"The effect of tetrandrine combined with cisplatin on proliferation and apoptosis of A549\/DDP cells and A549 cells.","volume":"17","author":"Ye","year":"2017","journal-title":"Cancer Cell Int"},{"key":"R47-20251121","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.canlet.2011.01.022","article-title":"Combination of Tetrandrine with cisplatin enhances cytotoxicity through growth suppression and apoptosis in ovarian cancer in vitro and in vivo.","volume":"304","author":"Zhang","year":"2011","journal-title":"Cancer Lett"},{"key":"R48-20251121","doi-asserted-by":"crossref","first-page":"648","DOI":"10.2174\/0115672018341709241121092617","article-title":"Preparation and evaluation of tetrandrine nanocrystals to improve bioavailability.","volume":"22","author":"Xue","year":"2025","journal-title":"Curr Drug Deliv"},{"key":"R49-20251121","doi-asserted-by":"crossref","first-page":"e2400274","DOI":"10.1002\/ardp.202400274","article-title":"Advances in nano-preparations for improving tetrandrine solubility and bioavailability.","volume":"357","author":"Ling","year":"2024","journal-title":"Arch Pharm (Weinheim)"},{"key":"R50-20251121","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1038\/aps.2013.62","article-title":"ROS generated by CYP450, especially CYP2E1, mediate mitochondrial dysfunction induced by tetrandrine in rat hepatocytes.","volume":"34","author":"Qi","year":"2013","journal-title":"Acta Pharmacol Sin"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000045860","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T23:01:47Z","timestamp":1763766107000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000045860"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,14]]},"references-count":50,"journal-issue":{"issue":"46","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000045860","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,14]]},"assertion":[{"value":"2025-07-28","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-09","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}